-
Apeloa Pharmaceutical Invests in Ji Xing Pharmaceuticals’ Series D Financing Round
•
China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced its participation in the Series D financing round of fellow Chinese firm Ji Xing Pharmaceuticals, contributing USD 2.75 million for a 0.58% stake in the Shanghai-based company. The investment round also saw contributions from Ji Xing’s founder, RTW Holding Limited, and…
-
Organon Inks Deal to Acquire Dermavant, Bolstering Dermatology Portfolio with Vtama Cream
•
US healthcare company Organon (NYSE: OGN) has announced a definitive agreement to acquire Dermavant, a Roivant (NASDAQ: ROIV) subsidiary focused on dermatological treatments. The acquisition is primarily driven by Dermavant’s Vtama (tapinarof) cream, a 1% topical formulation approved for plaque psoriasis and currently under regulatory review for atopic dermatitis (AD).…
-
Beijing’s MoleculeMind Secures Series A Funding to Accelerate AI Protein Design Innovations
•
MoleculeMind, a Beijing-based AI protein design platform, has reportedly secured a Series A financing round, raising hundreds of millions of renminbi. The funding was co-led by Cherami Investment and Shenzhen Capital Group, with participation from Sense Capital and EBI Investment. The capital raised will be directed towards enhancing the company’s…
-
CSA Medical Inc. Secures USD 53 Million in Series D Financing to Advance Cryotherapy Treatment
•
CSA Medical Inc., a U.S.-based medical technology company, has successfully closed a Series D financing round, securing USD 53 million in capital. This financing was co-led by TVM Capital Life Science and China-focused Yonjin Ventures, with significant participation from existing investors including SV Health Investors, Ascension Ventures, First Analysis, Blue…
-
JHM Biopharma Secures Over USD 28 Million in Series B+ Financing to Boost Pipeline Development
•
JHM Biopharma, a protein drug developer based in Hangzhou, has reportedly secured over RMB 200 million (USD 28 million) in a Series B+ financing round. This follows a Series B funding of RMB 100 million (USD 14 million) in May, bringing the total funds raised to RMB 350 million (USD…
-
Rigel Pharmaceuticals Strikes Deal with Kissei for Development and Commercialization of Rezlidhia in East Asia
•
Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), a biopharmaceutical company based in the U.S., has entered into a license and supply agreement with Japan’s Kissei Pharmaceutical Co., Ltd. The agreement grants Kissei the rights to develop and commercialize Rigel’s Rezlidhia (olutasidenib) across Japan, South Korea, and Taiwan. Rezlidhia is an oral isocitrate…
-
Jiangsu Suzhou Launches $843 Million Biomedicine Fund to Boost Pharma and Medical Device Innovation
•
The Jiangsu Suzhou Biomedicine Industry Special Fund of Fund (FoF), a colossal pharmaceutical investment vehicle with a capitalization of RMB 6 billion (USD 843 million), debuted last week. This 15-year financial instrument is designed to target and catalyze growth in innovative drugs, medical R&D, medical devices, healthcare services, and synthetic…
-
CGeneTech Secures RMB 100 Million in Series C Financing to Advance Drug Commercialization and Clinical Pipeline
•
CGeneTech (Suzhou, China) Co., Ltd., a biopharmaceutical company based in China, has reportedly secured a Series C financing round totaling RMB 100 million, led by Tongren Boda Investment. The capital raised will be strategically allocated towards the commercial-scale manufacturing and marketing efforts for its flagship product, centagliptin, a Category 1…
-
Tiantan Biological to Acquire Wuhan Zhongyuan Ruide for $185 Million, Expanding Plasma Resources
•
BEIJING—Beijing Tiantan Biological Products Co., Ltd (Tiantan Biological, SHA: 600161) has announced that its subsidiary, Chengdu Rongsheng Pharmaceutical Co., Ltd (Chengdu Rongsheng), intends to acquire 100% equity interest in Wuhan Zhongyuan Ruide Biological Products Co., Ltd (Zhongyuan Ruide), a wholly-owned subsidiary of CSL Behring Asia Pacific Limited (CSL Asia Pacific),…
-
MicroPort CardioFlow to Acquire RMB 380 Million Shanghai Assets for Global HQ Expansion
•
China-based MicroPort Scientific Corp. (HKG: 0853) has announced that its spin-off, MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), will acquire a 100% stake in Shanghai Heart Forever Medical Technology Co., Ltd. The acquisition, valued at up to RMB 380 million, will be executed through a transfer from its sister company,…
-
Leaderna Therapeutics Secures RMB 100 Million in Funding to Accelerate Nucleic Acid Drug Development
•
CHENGDU—Leaderna Therapeutics Ltd, a pioneering nucleic acid drug developer, has reportedly secured nearly RMB 100 million in a recent financing round spearheaded by Hygeia Capital. The syndicate of investors includes CAS STAR, Chengdu Biocity Jingchuang Equity Investment Fund, CS Ventures, and other prominent firms. The newly raised capital is earmarked…
-
China’s WORK Medical Technology Targets U.S. Market with Upcoming IPO
•
China-based WORK Medical Technology Group Ltd has priced its initial public offering (IPO) at USD per share for a total of 2,000,000 ordinary shares. The shares have received approval for listing on the Nasdaq Capital Market and are set to begin trading on August 23, 2024, under the ticker symbol…
-
UCB Agrees to USD 680 Million Divestment of China Neurology and Allergy Business to CBC Group and Mubadala
•
UCB, a Belgium-based biopharmaceutical company listed on the Brussels Stock Exchange (FRA: UNC), has announced the signing of a definitive agreement to divest its established neurology and allergy business in China. The transaction involves the sale to two prominent investment firms, the Singapore-based CBC Group and the Abu Dhabi-based Mubadala,…
-
Suzhou-Based Medical Device Innovator Ensurge Secures RMB 100 Million in Latest Financing Round
•
Ensurge, a cutting-edge medical device manufacturer headquartered in Suzhou, is reportedly in the spotlight for securing a new round of financing that has yielded RMB 100 million. The funding round saw participation from a consortium of investors including TPIC, Legend Capital, and Peakview Capital. The capital raised is earmarked for…
-
Bone Index Secures Financing to Expand Manufacturing and Promote Diagnostic Technology Globally
•
Bone Index, a Finland-based medical technology company specializing in bone diagnostics, has announced the successful completion of a new financing round, with the exact amount remaining undisclosed. The round was spearheaded by Lynx Financial, a Shanghai-based fund with a dedicated focus on healthcare and life sciences, and was supported by…
-
Finland’s Bone Index Partners with Lynx Financial for APAC and North American Market Expansion
•
HELSINKI—Bone Index, a pioneering medical technology company headquartered in Finland, has announced the successful completion of a new financing round, with the exact amount remaining undisclosed. The round was led by Shanghai-based Lynx Financial, a fund with a dedicated focus on healthcare and life sciences, and was supported by contributions…
-
Shineyo Medical Secures RMB 100 Million in Series A+ Funding for Cardiac and Vascular Devices
•
Shineyo Medical, a Shanghai-based manufacturer of electrophysiological and peripheral interventional devices, has reportedly secured nearly RMB 100 million (USD 13.9 million) in a Series A+ financing round. The funding was spearheaded by Guangzhou Jinkong Fund, with additional investments from Zhuopu Investment fund, Jinxin Capital, and Zhangjiagang Industrial Capital, along with…
-
Hygeia Healthcare Holdings Acquires Chang An Hospital in Deal Valued at RMB 1.66 Billion
•
Hygeia Healthcare Holdings Co., Ltd, a Shanghai-based medical investment and healthcare group, has announced the completion of an acquisition, securing a 100% stake in Chang An Hospital, a state-owned Class 3A general hospital. The transaction, which is reported to have already been finalized, involved a consideration of approximately RMB 1.66…
-
Eisai and SEED Therapeutics Join Forces on Molecular Glue Degraders for Neurodegeneration and Cancer
•
Eisai Co., Ltd (TYO: 4523), a Japanese pharmaceutical company, and SEED Therapeutics Inc., a U.S. biotech firm, have announced their intention to enter into a research collaboration aimed at developing novel molecular glue degraders for neurodegenerative diseases and oncology. Eisai will leverage SEED’s expertise in targeted protein degradation (TPD) to…
-
Shanghai Aims to Become Capital Market Hub for High-Quality Science and Innovation Companies
•
The Shanghai municipal government has unveiled a comprehensive set of measures designed to enhance the city’s capital market’s role in fostering the high-quality development of science and innovation companies. The strategic initiative aims to establish Shanghai as a premier investment and financing hub for new quality productivity, a showcase for…
